Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Medtronic
Johnson and Johnson
Moodys
Harvard Business School

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,920,122

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,920,122
Title:Compositions and methods to enhance the immune system
Abstract: The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host\'s immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host\'s immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
Inventor(s): van den Berg; Timo Kars (Amsterdam, NL)
Assignee: Stichting Sanquin Bloedvoorziening (Amsterdam, NL)
Application Number:15/145,365
Patent Claims:1. A composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against a cancer cell, wherein said therapeutic compound is a therapeutic antibody comprising a human or non-human primate IgG Fc portion, wherein the therapeutic antibody induces antibody-dependent cellular cytotoxicity (ADCC), and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha., wherein said agent is an anti-SIRP.alpha. antibody or a Fab fragment, a F(ab')2 fragment or a scFv fragment thereof.

2. The composition according to claim 1, wherein the cancer cell is a non-Hodgkin's lymphoma cell, a breast cancer cell, a chronic lymphocytic leukemia cell or a colorectal cancer cell.

3. The composition according to claim 1, wherein the therapeutic antibody is selected from the group consisting of rituximab, trastuzumab, alemtuzumab, cetuximab, and panitumumab.

4. The composition according to claim 3, wherein the cancer cell is a non-Hodgkin's lymphoma cell, a breast cancer cell, a chronic lymphocytic leukemia cell, or a colorectal cancer cell.

5. The composition according to claim 1, wherein the cancer cell is a non-Hodgkin's lymphoma cell or a chronic lymphocytic leukemia cell.

6. The composition according to claim 1, wherein the cancer cell is a breast cancer cell.

7. The composition according to claim 1, wherein the cancer cell is a colorectal cancer cell.

8. The composition according to claim 1, wherein the therapeutic antibody comprises a human IgG1 Fc portion or a human IgG3 Fc portion.

9. A composition comprising (i) a therapeutic antibody selected from the group consisting of rituximab, trastuzumab, alemtuzumab, bevacizumab, cetuximab, and panitumumab, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRP.alpha., wherein said agent is an anti-SIRP.alpha. antibody or a Fab fragment, a F(ab')2 fragment or a scFv fragment thereof.

10. The composition according to claim 9, wherein the therapeutic antibody is rituximab.

11. The composition according to claim 10, wherein the cancer cell is a non-Hodgkin's lymphoma cell or a chronic lymphocytic leukemia cell.

12. The composition according to claim 9, wherein the therapeutic antibody is trastuzumab.

13. The composition according to claim 12, wherein the cancer cell is a breast cancer cell.

14. The composition according to claim 9, wherein the therapeutic antibody is alemtuzumab.

15. The composition according to claim 14, wherein the cancer cell is a chronic lymphocytic leukemia cell.

16. The composition of claim 9, wherein the therapeutic antibody is cetuximab.

17. The composition of claim 16, wherein the cancer cell is a colorectal cancer cell.

Details for Patent 9,920,122

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 1997-11-26 ⤷  Free Forever Trial 2028-04-23
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Free Forever Trial 2028-04-23
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Free Forever Trial 2028-04-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.